Henry Schein enters exclusive distribution agreement with CytoChip

Henry Schein (HSIC) entered into a new exclusive distribution agreement with CytoChip for its flagship product, the CitoCBC system, a U.S. Food and Drug Administration 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.